Traders should monitor upcoming SCY-247 Phase 1 topline data in late 2026 and potential milestone payments from GSK on BREXAFEMME sales, which could provide additional non-dilutive funding and catalyze further value creation.
SCYX drugs
SCYX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $6.34entry
- T+1 · 9mo ago +0.95%α +2.26% · $6.40
- T+5 · 8mo ago +12.34%α +14.58% · $7.12
- T+20 · 8mo ago +12.04%α +15.83% · $7.10
- T+60 · 6mo ago −15.93%α −27.23% · $5.33
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Scynexis reported a significant year-over-year revenue increase to $20.6 million in 2025, driven by a $24.8 million one-time payment and catchup revenue from GSK, while R&D and SG&A expenses declined. The company ended the year with $56.3 million in cash, providing a runway of over two years, and advanced its SCY-247 program with Phase 1 IV dosing initiated and expanded access planned for 2026.
Key Financial Metrics
Key Facts
- Revenue surged to $20.6 million in 2025 from $3.7 million in 2024, primarily due to $24.8 million in non-refundable payments and catchup revenue from GSK.
- Net loss narrowed to $8.6 million from $21.3 million in 2024, with R&D expenses decreasing 15.6% year-over-year.
- Cash, cash equivalents, and investments totaled $56.3 million as of December 31, 2025, providing a cash runway of more than two years.
- SCY-247 IV formulation Phase 1 dosing initiated in February 2026, with topline data expected in second half of 2026; expanded access program planned for first half of 2026.
- FDA granted QIDP and Fast Track designations for SCY-247 in January 2026.
Financial Impact
Revenue increased by $16.9 million YoY; cash position improved by $24.8 million from GSK payment despite operating outflows.
Risk Factors
- Future revenue is heavily dependent on GSK's commercial success with BREXAFEMME and potential milestone payments.
- SCY-247 development remains early-stage; clinical setbacks could impact valuation and funding strategy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249748 |
Track record
14 reports on SCYX
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
- Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
- Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
- Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
- Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
- May 22, 202625w ago 8-K Neutral 4/10 Entry $5.45 to $5.33 Now $2.91 −46.59% ▼ −2.17% −3.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers